Zimmer beats, ups guidance

 

Zimmer Biomet beats Q2 estimates with non-GAAP EPS $2.07, revenue $2.2B, raises 2026 revenue growth guidance to 3.9%–4.9% and EPS outlook to $8.47–$8.59

• 2026 EPS outlook raised to $8.47–$8.59 per share from prior guidance range of $8.40–$8.55.
• Robotics and hip innovations boosted Zimmer Biomet's U.S. growth during Q2, coinciding with the company's raised 2026 guidance.
• Zimmer Biomet detailed its Q2 segment results, highlighting performance across its various operating segments for the quarter.

https://finviz.com/stock?t=ZBH&p=d